Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australian Regulator On The Highs & Lows Of Project Orbis

Executive Summary

The US FDA-led initiative for collaborative submission and review of new cancer drugs has produced a number of benefits since it was introduced in 2019, including more “robust” regulatory decisions and earlier market access, the DIA Europe 2022 conference heard. 

You may also be interested in...



Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch

Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.

EU Countries Slam Transferable Exclusivity Voucher Proposal

A group of EU member states has written to the European Commission saying that an exclusivity voucher scheme intended to stimulate R&D into new antimicrobials will stifle innovation by competitor companies and push up costs for national health systems.

Stakeholders Gather To Discuss Pandemic Response And Next Steps

As Europe’s health emergency body HERA approaches its first anniversary, an unprecedented range of stakeholders including industry bodies will be meeting in December to discuss HERA’s achievements, while a separate event will showcase the next generation of vaccines for COVID-19 and other infections.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel